Drug Trial Radar · NCT05455619
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Aug 26, 2022
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- SynDevRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy. The purpose of this study is: * to characterize the safety of the triplet drug combination consisting of either alpelisib or capivasertib (per the treating oncologist's choice) and fulvestrant plus evexomostat, * to test whether evexomostat, when given in combination with either alpelisib or capivasertib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number or dose of anti-diabetic medications needed to control the hyperglycemia for metabolically normal patients and those deemed at risk for capivasertib and alpelisib-induced hyperglycemia (insulin resistance, as measured by HOMA-IR, baseline elevated HbA1c or well-controlled type 2 diabetes), and * to assess preliminary anti-tumor efficacy for each combination and changes in key biomarkers and quality of life in this patient population.
Conditions
- HR+/HER2-negative Breast Cancer
- Metastatic Breast Cancer
Interventions
EvexomostatDrug
Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse EventsTime frame: Up to 48 months
- Hyperglycemic EventsTime frame: Up to 42 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Loma Linda University Cancer Center
Loma Linda, California · Recruiting
Hoag Memorial Hospital Presbyterian
Newport, California · Recruiting
SHARP Healthcare
San Diego, California · Recruiting
Miami Cancer Institute at Baptist Health
Miami, Florida · Recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois · Recruiting
Trinity Health
Ypsilanti, Michigan · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Doctors Hospital of Laredo
Laredo, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.